iShares Nasdaq Biotechnology exchange-traded fund (ETF) (IBB), which tracks the group of 211 stocks, has soared sharply since mid-Mach hitting an all-time high of $136.20 on Monday before reversing some gains in the past few sessions. It is trading at $132.57 on Friday morning.
The robust upside momentum in the last two months is driven by the sentiment that biotech ETFs could benefit from increased spending on drugs and higher investor interest.
However, traders warned that buying at current levels should tread carefully because some of the big names that account for the biggest chunk of IBB portfolio are breaking down.
Amgen (NYSE: AMGN) is the other big stock that is struggling over the past few weeks.
The top four holdings of iShares Nasdaq Biotechnology ETF accounts for 30% of total value and the top ten holdings represent 52.47% value of ETF.
“If Gilead and Amgen start to break down, it could be a problem for the group,” Miller Tabak chief market strategist Matt Maley (pictured) told CNBC’c Trading Nation on Wednesday.
“Now, nobody wants to short any of these names because if you get a nice discovery on [a] Covid-19 vaccine, the group’s going to go do very nicely. But I just think people don’t want to be aggressive after the big move we’ve had, given that these two stocks are starting to show some cracks,” he added.
It’s time to be selective in placing investments, according to Mark Tepper, the president and chief executive officer of Strategic Wealth Partners.
“This is not a situation where I’d be looking to just blindly buy the group and hop into the IBB ETF,” he said. “Price matters.”